Collegium Announces FDA Acceptance of IND Application for Abuse-Deterrent, Hydrocodone DETERx® by longitudeadmin | Jan 21, 2016 | Portfolio News
Esperion Therapeutics Announces Initiation of Phase 3 Clinical Program With Long-Term Safety and Tolerability Study by longitudeadmin | Jan 13, 2016 | Portfolio News
Esperion Therapeutics Announces Initiation of Phase 2 Clinical Study of Bempedoic Acid in Patients Treated With High-Dose Statin Therapy by longitudeadmin | Jan 12, 2016 | Portfolio News
Aimmune Therapeutics Enrolls First Patient in Phase 3 PALISADE Trial of AR101 for the Treatment of Peanut Allergy by longitudeadmin | Jan 11, 2016 | Portfolio News
Collegium Pharmaceutical, Inc. Prices Public Offering of $55.0 Million of Common Stock by longitudeadmin | Jan 8, 2016 | Portfolio News
